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Abstract
Antibodies’ protective, pathological, and therapeutic properties result from their considerable diversity. This diversity is
almost limitless in potential, but actual diversity is still poorly understood. Here we use deep sequencing to characterize the
diversity of the heavy-chain CDR3 region, the most important contributor to antibody binding specificity, and the
constituent V, D, and J segments that comprise it. We find that, during the stepwise D-J and then V-DJ recombination
events, the choice of D and J segments exert some bias on each other; however, we find the choice of the V segment is
essentially independent of both. V, D, and J segments are utilized with different frequencies, resulting in a highly skewed
representation of VDJ combinations in the repertoire. Nevertheless, the pattern of segment usage was almost identical
between two different individuals. The pattern of V, D, and J segment usage and recombination was insufficient to explain
overlap that was observed between the two individuals’ CDR3 repertoires. Finally, we find that while there are a near-infinite
number of heavy-chain CDR3s in principle, there are about 3–9 million in the blood of an adult human being.
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Introduction
The human adaptive immune system consists of B cells, which
secrete antibodies, and T cells, which target infected or otherwise
aberrant cells through their T cell receptors (TCRs). Both cell
types have been of longstanding interest for their roles in vaccines,
infections, and autoimmune diseases, as well as cancer [1,2].
Underlying these roles is the ability of B and T cells to generate a
seemingly infinite number of different antigen specificities from the
finite genetic material encoded in the germline genome.
Several mechanisms are responsible for generating this diversity.
The most fundamental is somatic recombination [3]. This is a
combinatorial process in which any one of several gene segments
from each of two or three sets of segments are recombined to form
a single novel gene (a highly ordered and regulated process). Each
antibody molecule is made up of the protein products of two such
genes, called heavy chain and light chain. The heavy-chain gene is
constructed, through somatic recombination, of three gene
segments, called V, D, and J; there are 56 V, 23 D, and 6 J
segments in the human genome [4]. The sequence from the V-D
to the D-J junction, spanning the entire D segment, is called
complementarity determining region (CDR) 3 and encodes part of
the heavy chain that makes physical contact with the antigen. It is
the single most important determinant of an antibody’s antigen
specificity [5,6]. Hence detailed descriptions of CDR3 diversity are
a prerequisite for understanding antibody responses to vaccines
and infections and in autoimmunity in fine detail—the level of
detail required for rational approaches to development of the next
generation of diagnostics and therapeutics [1,2].
There has been growing interest in using high throughput
sequencing for describing antibodies [7,8] and TCR [9,10,11,12].
Recent studies have used sequencing to describe the antibody
repertoire in zebrafish [13], to estimate the diversity of TCR in
humans [12], and to monitor residual disease in leukemia patients
[14]. The B cell repertoire in humans and mice has been the
subject of a number of detailed studies, especially of antibody
responses to various diseases, but not typically at the scale offered
by high-throughput sequencing [15,16,17,18,19,20,21].
Since the diversity of antibody sequences depends on VDJ
recombination, a number of previous studies have investigated the
diversity of VDJ joints expressed in response to specific infections,
malignancies, and autoimmune diseases [15,16,17,18,19,20,21].
They showed that for many exposures, genetically different
individuals produce antibodies with the same heavy- or light-
chain V(D)J combinations [22,23,24,25]. This has been observed
most often in antibody responses to bacterial polysaccharide
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protective and vaccine responses against infections by a number of
medically important life-threatening bacteria, such as Haemophilus
influenzae and Streptococcus pneumoniae [26]. One of the best-known
examples is the response to the childhood vaccine for H. influenza
typeB,inwhich protective antibodiesuseV segmentVH3-23,either
J segment JH4o rJ H6, and a D that results in a heavy-chain CDR3
that contains the protein sequence GYGF/MD [26]. Studies have
shown the existence of so-called public sequences [27] (overlap
among the repertoires of different individuals), an unlikely
occurrence if repertoires are shaped exclusively by chance.
In this context, we sought to describe the baseline diversity of V,
D, J, and CDR3 repertoires in antibody heavy-chain genes in
human and mouse using high-throughput sequencing with
particular attention to the roles of somatic recombination and
positive and negative selection.
Materials and Methods
Using 454 sequencing [28], we sequenced antibody heavy-chain
VDJ-rearranged genes from two healthy, genetically unrelated
young adult male donors. We used variants we developed of
primers that are well known from clinical laboratory medicine for
diagnosing clonal rearrangements in human leukemias [29]. We
also sequenced VDJ-rearranged genes from pooled spleens from
C57BL/6 mice to begin to understand which characteristics of
these immunomes are specific to humans and which apply also to
this model system.
Sample collection
For human, PBMC were isolated from 4610 ml of peripheral
blood drawn from one male donor and 2610 ml from a second
male donor using BD Vacutainer CPT cell preparation tubes (BD)
in compliance with the institutional review board at our institution
(protocol number 0510001399 of the Brigham and Women’s
Hospital Committee on the Use of Humans as Experimental
Subjects, Brigham and Women’s Hospital, Boston, MA; this
protocol was considered exempt after review by the Committee
pursuant to Federal regulations, 45 CFR Part 46.101(b)(4)). For
mouse, total spleen was collected from 4 C57BL/6 mice and B
cells isolated magnetically (MidiMACS B Cell Multisort Kit II;
Miltenyi). For both species, total DNA was then isolated by
standard methods (Qiagen). Mice were housed and cared for
under specific pathogen-free conditions in accordance with
protocol number 03341, approved by Harvard Medical School
IACUC guidelines.
Amplification and sequencing
Recombined heavy chain fragments were amplified from DNA
obtained as above using a subset of immunoglobulin VH FR2
(VH1-FR2, VH2-FR2, VH3-FR2, VH5-FR2, and VH6-FR2;
VH4-FR2 and VH7-FR2 had redundant coverage) or FR3 (VH1-
FR3 through VH6-FR3 but not VH7, which was redundant with
VH1) and JH BIOMED-2 primers [29] for human and a multiplex
cocktail of four forward primers with homology to heavy-chain
FR3 (59-AAGTTCAAGGGCAAGGCC-39,5 9-CTCCAAGAGC-
CAAGTTTTCTT-39,5 9-CAATCTCCAAGGATACCTCCA-39,
59-CGITTCACCATCTCCAGAGA-39) and two reverse primers
with homology to J consensus (59-CTTACCTGAGGAGACGG-
TGAC-39 and P-AGGACTCACCTGAGGAGAC-39) for mouse.
All samples were amplified by PCR for 35 cycles with
PlatinumTaq (Invitrogen) with the following conditions: 1.5 mM
MgCl2; melt at 95uC for 19000, anneal at 60uC for 19000, extend at
72uC for 19300 and then sequenced by 454 sequencing.
Primer design
Primers were designed using an approach developed in house
and designed to attain maximum coverage of a heterogeneous set
of target sequences with a minimal, non-self-hybridizing primer
set. Briefly, for each set of targets, we made a list of all primer-
length substrings with low predicted self-hybridization. We then
evaluated the number of targets ‘‘hit’’ by each substring, allowing
up to three (non-terminal) mismatches. The substring with the
most hits was added to the primer set. The process was repeated
for the remaining targets until we had a set of primers that hit all
targets. We then added, removed, or changed single nucleotides to
achieve similar melting temperatures. V segments identical over
the sequenced region were placed into equivalence classes.
Sequence assignment
V, D, and J segments were assigned and aligned to sequences
through a two-step method. In the first step, the segment with the
most substrings in common with the sequence was assigned to that
segment. The longer the segment, the better this kind of approach
does; therefore we expected the highest accuracy in assigning V
segments, which are longest, followed by J, then D. The V segment
was assigned first, followed by J, then D; we required that V and J
be at opposite ends of the sequence and D be between them. (D
regions, which are short, cannot be reliably assigned in sequences
with high somatic hypermutation.) When multiple segments tied
for having the same number of substrings in common with the
sequence, the sequence was marked as an ambiguous assignment
and was removed from subsequent analysis. In the second step,
megablast (v2.2.23) was used to align the assigned segment to the
sequence.
For analysis of individual recombination events, we then used a
substring comparison similar to step 1 to group sequences into
clusters [13], and chose a representative sequence for VDJ
analysis. This alignment provided coordinates from which chew-
backs and N- or P-nucleotide additions were calculated. Following
earlier reports [30], sequences with V and J chewbacks of $30
nucleotides were removed from analysis.
Validation of annotation
We validated our approach on synthetic data sets consisting of
tens of thousands of VDJ-recombined sequences that we produced
in silico. For each synthetic data set, the number of bases removed
by exonucleotide chewback, added by nontemplated nucleotide
insertion, and mutated by somatic hypermutation was chosen
according to previous reports [23,31,32,33,34,35,36]. Our method
correctly assigned 97–99% of V segments and 91–98% of J
segments in both human and mouse synthetic data sets; it was
incorrect for ,1% of these segments (,1% false positives). It
correctly assigned 65–67% of D segments in human but only 33%
in mouse, in which D segments are much shorter than in human; it
incorrectly assigned 5–10% of D segments. It is worth noting that
in most cases in which the D segment was incorrectly assigned, the
reason was the presence of mutations that made the sequence
more similar to a different D segment—that is, objectively
speaking, the incorrect assignment was a better match than the
correct assignment would have been. This is a consequence of D
segments being short and similar to each other in sequence.
Statistical analysis
In addition to basic statistics about the frequencies of each V, D,
and J, we investigated the statistical likelihood of preferential
pairing between segments (e.g., a given D with a given J). We did
this as follows.
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j was calculated for each pair by calculating the probability of
observing n instances of an ij pair given the frequencies of i and j
among all observations. For example, consider a hypothetical
genome with only two different V segments, V1 and V2, and two
different D segments, D1 and D2. Suppose we were to find that V1
and V2 each appeared in half of 100,000 V-D recombined
sequences, as did D1 and D2. If V-D pairing were random, one
would expect the combinations V1-D1, V1-D2, V2-D1, and V2-D2
should each appear 25% of the time, or in 25,000 sequences each.
But suppose the data show V1-D1 and V2-D2 in 50,000 sequences
each and V1-D2 and V2-D1 in zero sequences. The probability of
observing 50,000 V1-D1 or V2-D2 sequences by chance, given that
the segments each appear half the time, is very small; this suggests
preferential pairing between V1-D1 and V2-D2.
To determine if the probabilities at which each VD, DJ, and VJ
pair appeared in our data were statistically significant, we
compared these probabilities to the probabilities that we observed
in hundreds of in silico simulations. In each simulation, we
constructed 20,000–70,000 antibody sequences at random using
the same individual frequencies of V, D, and J segments observed
in our real data sets (the number of sequences chosen to be the
same as the number in our real data sets), assigned V, D, and J,
and recorded the frequencies at which each VD, DJ, and VJ pair
appeared in the simulation. In these simulations, in tens of
thousands of measurements of the frequencies of segment pairs,
95% of the calculated probabilities were p.0.1, and the minimum
probability observed was p=10
24.5 (=3.2610
25). Therefore, in
our real data, we considered probabilities less than 10
24.5 to be
statistically significant—i.e., less than what was observed by
chance. Preferential pairing was always confirmed in both
directions: for example, if V1 was found in twice as many D1-
containing sequences as expected, we confirmed that D1 was also
found in twice as many V1-containing sequences as expected.
Results
V, D, and J gene segments, as well as VDJ combinations,
appear at unequal frequencies in humans
We obtained 746,248 reads from a single human subject:
453,223 reads from FR3 to the consensus J region and 293,025
reads from FR2 to the consensus J region (Table 1). V segments
that were identical over these regions were combined into
equivalence classes. This process led to the identification of
52,011 clusters from the FR3-to-consensus-J reads and 14,848
clusters from the FR2 to consensus J reads, each cluster
representing a single VDJ recombination event.
We annotated sequences according to the V, D (where possible),
and J segments that comprised them (Fig. 1). V, D, and J gene
segments appeared at unequal frequencies, with a few segments
appearing very often and the majority appearing rarely, resulting
in highly skewed or long-tail distributions (Fig. 2a–c). The most
frequently observed V regions were VH4-59/61 (the VA
equivalence class), VH3-23, and VH3-48, consistent with previous
reports [7,37]. Only 10 V regions accounted for half of all clusters,
underscoring the long tail in Fig. 1a (oligoclonality index
[OI]=0.56 [38]). A similar pattern was observed from D regions,
with four of the 23 D segments—IGHD3-3, D3-10, D2-2, and D3-
22—accounting for half of all Ds (OI=0.60). The long-tail pattern
was least pronounced for J segments, since there are only six of
them, but J4 and J6 were by far the most frequently used,
consistent with prior reports [39] (OI=0.55). This pattern was
identical between the two sequenced individuals (Fig. 2d–g) with
an average difference of 1.1% across all segments.
Because V, D, and J segments appeared at unequal frequencies,
we expected that unique VDJ combinations, which are the
product of the segments, would appear at unequal frequencies as
well. Indeed, frequencies ranged from ,0.1% to 2.0% for the
1,829 different VDJ combinations observed in the FR3-to-J set
and 0.1% to 2.7% for 1,699 different combinations observed in
the FR2-to-J set, again with long tails (Fig. 2g). However, other
factors might also contribute to unequal frequencies of VDJ
combinations, including preferential pairing between segments or
Table 1. Number of Reads and Clusters.
Subject 1 Subject 2
FR2 to J FR3 to J FR3 to J
VJ reads 293,025 453,223 66,557
Clusters 14,848 52,011 6,226
Unique V and J 8,274 32,986 3,479
Unique V, D, and J 7,041 29,240 2,737
Average reads/cluster 19.7 8.7 10.7
doi:10.1371/journal.pone.0022365.t001
Figure 1. A five-step annotation methodology was used. Step 1:
New sequence was obtained through pyrosequencing. Step 2: Using a
word-counting strategy, the best-match V was determined. When there
was a tie for best match, or when the best match was nevertheless a
poor match, sequences were removed from subsequent V-D-J usage
analysis. The best-match V was then aligned to the new sequence using
megablast. Steps 3: The region that matched V was removed (grayed
out in the figure) and the same word-counting strategy was applied to
the remaining sequence to determine the best-match J sequence. As
with V, ties and poor matches were removed; the best-match J was
aligned using megablast. Step 4: The region that matched J was
removed (gray) and D was assigned and aligned to the remainder as in
Steps 2 and 3. Step 5: Using the alignments, exonucleotide chewback
and nucleotide addition were determined.
doi:10.1371/journal.pone.0022365.g001
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combination that each one harbors. We investigated each of these
possibilities in turn.
V, D, and J segments show minimal preferential pairing
We asked whether DJ, VD, and VJ segment pairings exhibit
preferential pairing—that is, whether particular pairs appear
more often or less often than one would expect by chance.
During somatic recombination, D and J segments recombine
first. We found that 16 of 186, or 8.6%, of observed DJ pairs
exhibited preferential pairing, for example, the D segment D3-9
and the J segment J3. Because D3-9 was observed in 2.9% of all
sequences, it was expected to appear in 2.9% of sequences that
contained J3. However, we found that D3-9 appeared in 6.0% of
J3-containing sequences (p=1.1610
26), or 6.0/2.9=2.1-fold
preferential pairing. Thus D3-9 and J3 pair about twice as often
as expected by chance. As another example, D3-22 was expected
to occur in 8.2% of J6-containing combinations, but was
observed in just 3.8% of them, less than half as often as
expected by chance (p=2.9610
245). Thus, D3-22 and J6 also
exhibit preferential pairing, though in this case it is a 2–3-fold
negative preference (a preference against pairing with each other).
The remaining 14 DJ pairs exhibited preferences somewhere
between these values.
V-DJ recombination follows D-J recombination. In contrast to
DJ pairs, only 0.3% (2 of 768) of VD associations showed
preferential pairing. Because D segments are very short—half have
fewer than 20 nucleotides—and since they lose nucleotides due to
chewback during recombination, we also looked for preferences
among VJ pairs, on the hypothesis that a J segment’s sequence or
flanking sequences could influence the choice of V (even though V
and J almost never [40] pair directly). Again, the effect was small:
just 1.3% of VJ pairs showed preferential pairing. These
observations were nearly identical between the two individuals.
There was no obvious correlation between the extent of
preferential pairing and the amount of microhomology
[41,42,43] between segments or the sequence of their recognition
signal sequences (RSSes; not shown). Thus the preferential pairing
that occurs among segments in VDJ recombination is almost all
during the first step of recombination, between D and J.
Figure 2. V, D, and J segment use in human is highly uneven. Lines indicate cumulative distributions (measured on right-hand side y-axis) (a)–
(c). Not all V segments are labeled on the x-axis. V, D, and J segments appear at similar frequencies in two different human subjects (d)–(f). Each point
corresponds to a single segment. Insets show cumulative distributions. VDJ combinations also appear unevenly, with the 100 most frequent VDJ
combinations responsible for 50 percent of all recombination events (g).
doi:10.1371/journal.pone.0022365.g002
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productive and nonproductive joins
We next asked whether these preferences and the frequencies of
VDJ combinations were determined during recombination, or
reflected subsequent positive or negative selection on B cells
expressing the resulting antibodies. To test whether selection
determines the frequency of VDJ combinations, we compared the
frequencies of VDJ combinations in productive vs. nonproductive
combinations. We considered nonproductive those rearrangements
that are either out of frame or contain stop codons. Because
nonproductiverearrangements arenot expressed,theyare notunder
selection; thus differences in the frequency of a given VDJ between
productive and nonproductive rearrangements would suggest that
cells are selected for or against based on the VDJ combination.
We calculated the difference in frequency for each combination
and, using synthetic data sets as benchmarks (see Methods), the
probability that this difference would be seen by chance. By this
approach, only 2% of VDJ combinations showed a statistically
significant difference between productive and nonproductive
rearrangements. In fact, we found less difference between pro-
ductive and nonproductive combinations in the actual data set
than in our benchmark sets, in which productive and nonproduc-
tive combinations are produced at random. Taken together, these
findings suggest that while selection for antigen specificity is known
to be important, VDJ combination alone does not determine
antigen specificity, in clinically healthy individuals.
Segment usage, pairwise preferences, and selection on
VDJ combinations in mice
We conducted the same analysis on VD, DJ, and VJ pairs, and
VDJ combinations, from C57BL/6 mice. These mice have 100 V,
10 D, and 4 J functional gene segments [44]. As in human, we
found ‘‘long tail’’ distributions for V, D, and J segment usage and
in VDJ combinations (OI=0.56, 0.52, and 0.68 for V, D, and J
respectively; Fig. 3a–d). Using the same methodology as above, we
found that 27.6% of DJ pairs showed statistically significant
preferential pairing—higher than in human—while VD and VJ
pairs showed almost no statistically significant preferential pairing
(0.0% and 1.1%, respectively). For example, D3-2 appeared in
19.4% of sequences overall, but in only 2.2% of J1-containing
sequences, an 8.7-fold negative preference (p=2610
272). Mean-
while, J3 appeared in 15.0% of all sequences but 20.7% of
sequences that contain D2-4, a 40% positive preference
(p=5610
28). Most preferences were less than 2-fold. As in
human, there were no significant differences between productive
and nonproductive combinations, suggesting that all VDJ (and
also VD, DJ, and VJ) combinations, once formed, are equally able
to contribute to functional antibodies.
Deep sequencing confirms overlap among CDR3
sequences between human subjects
Next, we inquired about similarities between the two human
individuals. There are approximately one billion B cells in the
human body, 10 million of which are produced and destroyed
each day. Consequently, a single individual can only ever express a
tiny fraction of the potential CDR3 repertoire. Yet CDR3s with
the same amino acid sequences have been observed in different
individuals, in antibodies and TCR [12,45]. We sought to
quantitate this for antibody heavy-chain CDR3s, and asked
whether it could happen by chance.
To do this, we built synthetic data sets with the same frequencies
of V, D, and J segments, the same chewback and N-nucleotide
addition profiles, comparable mutation rates, and the same
number of sequences, as our real data sets. Unsurprisingly, we
found that the number of sequences in common depends greatly
on the mutation rate used to create the data sets: the higher the
mutation rate, the fewer sequences in common between two sets.
For example, with a mutation rate of 0.05 (an average of one in
every 20 bases mutated per sequence), in 585 pairwise compar-
isons among 54 synthetic data sets, we found an average of 236
CDR3s in common (s.d., 15). Raising the mutation rate to 0.10, in
1,000 pairwise comparisons among 110 synthetic data sets, we
found an average of 75 CDR3s in common (s.d., 8). At the other
extreme, with a mutation rate of zero, the overlap was 1,292 (s.d.,
34). Meanwhile, in actual data from our two human subjects, we
found 279 CDR3s in common. We estimated the mutation rate in
our actual data sets as between 0.05 and 0.08, based on comparing
annotation with synthetic data sets that had varying mutation rates
(sequencing error makes precise determination of mutation rate
unreliable at this depth of sequencing). Thus although the overlap
between human subjects was only a fraction of the total CDR3
diversity, it was significantly more than was expected by chance
(p=0.002 for comparison with a mutation rate of 0.05;
p,,0.0001 for comparison to a mutation rate of 0.10).
Statistically, it is more likely that two short CDR3s will have the
same sequencethan two longerones (inthe limit,two CDR3s with a
length of just a single amino acid would have at least a 1:20, or 5%,
chance of overlap because there are 20 amino acids). Therefore we
expected the CDR3s that were shared between synthetic data sets,
as well as the CDR3s shared between our two human subjects,
would be shorter than CDR3s overall. In the synthetic data sets, the
lengths of shared CDR3s again depended on mutation rate. For a
mutation rate of 0.05, the shared CDR3s were less than half as long
as CDR3s overall: they had a modal length of 7 amino acids
(mean6s.d., 9.963.4; n=141,121) vs. a modal length of 15 for
CDR3s overall (15.063.8; n.3.1 million). The length of the shared
CDR3s decreased as the mutation rate increased. In contrast, in the
actual data from our human subjects, shared CDR3s were only
slightly shorter than the overall average: 12 (14.363.7; n=279) vs.
,15 amino acids in each of the two data sets (15.663.8 and
15.363.6; n=189,965 and 24,979, respectively). The CDR3s
shared by the two human subjects were significantly longer than the
shared CDR3s in the synthetic data sets (12 vs. 7 amino acids; V, D,
and J segment usage was similar in both shared sets). Thus both the
degree of overlap and the length of the shared CDR3s were greater
than expected by chance, arguing that the overlap in CDR3
sequence among individuals is biological and not a statistical
artifact. CDR3s in the human data sets also shared other properties
not seen in the synthetic data sets. Amino acid charge was
20.0561.40 and 0.0961.39 for productive joins and 1.1261.55
and 1.1061.51 for nonproductive joins in the two individuals.
These differed from charge properties in the synthetic data sets
(20.3961.17 for productive and 0.7461.28 for nonproductive
representative synthetic datasets), suggesting selection for CDR3s
that carry a slightly more positive charge.
Estimate of total antibody heavy-chain CDR3 diversity in
human
Finally, deep sequencing allowed us to estimate the total
number of productive heavy-chain CDR3s in each of our two
human subjects. We did this as follows. In the first subject, the first
1,000 FR3-to-J sequences that we obtained contained 953 unique
productive CDR3s. The next set of 1,000 added another 885
unique productive CDR3s; the third set added another 831, and
so on, in a pattern of logarithmic decay (R
2=0.98; not shown). In
general, each subsequent set added fewer unique CDR3s. The
same pattern was observed in the FR2-to-J sequences, and in the
Antibody Heavy-Chain Repertoires in Humans
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axis) (a)–(c). Out of space considerations only V segments present at $1% are shown. Insets show cumulative distributions. VDJ combinations also
appear unevenly, with the ,200 most frequent VDJ combinations responsible for 50 percent of all recombination events (d).
doi:10.1371/journal.pone.0022365.g003
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us to calculate, for each sample, the point at which no additional
sequences would be observed. This produced an estimate of
48,000–69,000 unique productive heavy-chain CDR3s from
samples from the first subject and 12,500 unique productive
heavy-chain CDR3s from samples from the second subject.
Because the number of CDR3s in common between two 10-ml
samples from the same subject was small relative to the total
number of CDR3s in each sample (not shown), assuming the body
has 5 liters of blood, we multiplied to get an upper bound of 3 to 9
million heavy-chain CDR3s in the blood of an adult human.
Discussion
The specificity of adaptive immune responses is encoded in the
sequences of recombined antibody and TCR genes. This makes
sequencing a useful modality for dissecting immune responses, as
has long been recognized. Since the first studies on mice over two
decades ago [23,31,46], a central question has been how similar
are immune responses between different individuals. This is
related to another long-standing question: what is the actual—as
opposed to the potential or theoretical [7]—diversity of the
adaptive immune response in humans? The answers bear on the
feasibility of developing sequenced-based diagnostics to monitor
specific immune responses in vaccination, infection, cancer, and
autoimmunity, and the general state of the immune system in
immunodeficiency states like immunosuppression and aging.
Here we show just how important the first step in generating
diversity—the choice of V, D, and J segments during somatic
recombination—is for determining antibody diversity. We find
that in humans the VDJ repertoire is almost entirely set by
whatever genetic controls determine the selection of one V, D, or J
segment over another, with only a small bias of preferential pairing
of certain Ds with certain Js. The most frequently used Vs and Ds
that we observed were the same as those observed in previous
single-cell sequencing studies [39]. The scale of those studies was
too small to provide accurate or precise statistics on all segments to
compare with our results, but was sufficient to provide statistics on
the frequencies of V and D families, and also the six J segments.
We found more preferential pairing in mouse than in human,
again limited to DJ pairs. But on the whole, the unequal
frequencies at which heavy chains with different VDJ combina-
tions appear depend on the unequal frequencies at which their
component segments are chosen for recombination—and not on
positive or negative selection acting on cells that express certain
VDJ combinations and not others. We note that the long-tail
distributions we observed for V and D segments corroborate
previous reports [39] and are similar to what was seen for TCR
beta-chain V-region usage [47]. At a genetic level, recombination
depends on recombination signal sequences (RSSs) associated with
each segment [3]. While it is known that variations in the
canonical RSS can decrease recombination efficiency [48], and
thus decrease the frequency at which a given gene segment is
chosen for recombination, we observed no precise correspondence
between RSS sequence and gene segment frequency.
Previous studies found that the overlap in TCR CDR3s among
mice resulted from the uneven usage of gene segments [11]. While
uneven usage is necessary to explain the overlap of CDR3s
observed between our two human subjects, we show that it is not
sufficient. Controlling for V, D, and J usage, exonucleotide
chewback and N-nucleotide addition, and (as much as possible)
mutation rate, we nevertheless observed significantly more overlap
than was expected by chance, reminiscent of the unexpectedly
high overlap among TCR observed in recent studies [12]. Also,
the lengths of the overlapping CDR3s differed substantially from
the lengths of overlapping CDR3s in synthetic data sets, and was
much closer to the length profile of CDR3s overall, further
suggesting that the observed overlap was not simply a function of
V, D, and J segment recombination. The segment usage,
chewback, nucleotide addition, and mutation rate we used in
our synthetic data sets amount to a model of antibody heavy-chain
gene formation; the observed overlap is not explained by our
model. While it is conceivable that controlling for other statistical
features in our model could make our synthetic data sets closer
approximations of real ones, we consider it unlikely that it would
make enough of a difference to substantially increase the number
of CDR3s in common between synthetic data sets, or double their
length. The alternative explanation is convergence based on
biological factors, including positive selection for B cells that
express antibodies with these heavy-chain CDR3s.
Our estimate of total antibody heavy-chain CDR3 diversity is
roughly the same order of magnitude as estimates of heavy-chain
TCR-beta diversity [10,47]. However, many questions remain.
First, although heavy-chain CDR3 is the most important
determinant of antigen specificity, it is not the only one. Sequence
variation in CDR1 and CDR2 remain to be investigated, as does
the larger issue of patterns of pairing between heavy chain and
light chain. Combinatorial libraries built from human heavy- and
light-chain sequences have been produced [7], but the diversity of
heavy-light chain pairs in humans in vivo, as opposed to in synthetic
libraries [37,49], has not yet been directly characterized. Second,
the frequency of each CDR3—meaning the number of B cells,
clonally related, that express that CDR3—remains uncertain,
since PCR amplification can introduce biases in quantitation.
Third, variation among functional subsets of B cells, such as naı ¨ve
and memory B cells and plasma cells, as well as antigen-specific B
cells, in different states of health and disease, has yet to be
investigated in similarly fine detail. However, our technique and
results help establish a basis with which to design immune
sequencing studies to address these and other questions.
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